Neuroprotection has been suggested as a function of the endocannabinoid system, and findings that CB1 agonists protect against cerebral ischemia and that CB1 deletion enhances the severity of ischemia–reperfusion injury in mice [34,35,36] suggest that it could also be targeted for the treatment of stroke. The gene discussed is CNR1; the disease is Stroke.